Abstract
Tamoxifen is a selective estrogen receptor modulator. In this study we investigated whether or not tamoxifen reduces intracerebral hemorrhage (ICH)-induced brain injury in rats. In all experiments, adult male Sprague-Dawley rats received an injection of 100 μL autologous whole blood into the right basal ganglia. In the first set of experiments, rats were treated with tamoxifen (2.5 mg/kg or 5 mg/kg, i.p.) or vehicle 2 and 24 h after ICH and were killed at day 3 for brain edema measurement. In the second set of experiments, rats were treated with tamoxifen (5 mg/kg) or vehicle and magnetic resonance imaging (MRI), and behavior tests were performed at days 1, 7, 14 and 28. Rats were killed at day 28 for brain histology. We found that tamoxifen at 5 but not at 2.5 mg/kg reduced perihematomal brain edema at day 3 (p < 0.05). Brain histology showed that tamoxifen reduced caudate atrophy at day 28 (p < 0.01). Tamoxifen also improved functional outcome (p < 0.05). MRI demonstrated a tendency to smaller T2* lesions in tamoxifen-treated rats. However, two out of five rats treated with tamoxifen developed hydrocephalus. These results suggest that tamoxifen has neuroprotective effects in ICH, but the cause of hydrocephalus development following tamoxifen treatment needs to be examined further.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hurn PD, Macrae IM (2000) Estrogen as a neuroprotectant in stroke. J Cereb Blood Flow Metab 20:631–652
Nakamura T, Hua Y, Keep RF, Park JW, Xi G, Hoff JT (2005) Estrogen therapy for experimental intracerebral hemorrhage in rats. J Neurosurg 103:97–103
Xi G, Keep RF, Hoff JT (2006) Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol 5:53–63
Rau SW, Dubal DB, Bottner M, Gerhold LM, Wise PM (2003) Estradiol attenuates programmed cell death after stroke-like injury. J Neurosci 23:11420–11426
Harper MJ, Walpole AL (1967) A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J Reprod Fertil 13:101–119
Kimelberg HK, Feustel PJ, Jin Y, Paquette J, Boulos A, Keller RW Jr, Tranmer BI (2000) Acute treatment with tamoxifen reduces ischemic damage following middle cerebral artery occlusion. NeuroReport 11:2675–2679
Zhang Y, Jin Y, Behr MJ, Feustel PJ, Morrison JP, Kimelberg HK (2005) Behavioral and histological neuroprotection by tamoxifen after reversible focal cerebral ischemia. Exp Neurol 196:41–46
Obata T, Kubota S (2001) Protective effect of tamoxifen on 1-methyl-4-phenylpyridine-induced hydroxyl radical generation in the rat striatum. Neurosci Lett 308:87–90
Hua Y, Schallert T, Keep RF, Wu J, Hoff JT, Xi G (2002) Behavioral tests after intracerebral hemorrhage in the rat. Stroke 33:2478–2484
Okauchi M, Hua Y, Keep RF, Morgenstern LB, Schallert T, Xi G (2010) Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration. Stroke 41:375–382
Wu G, Xi G, Hua Y, Sagher O (2010) T2* magnetic resonance imaging sequences reflect brain tissue iron deposition following intracerebral hemorrhage. Transl Stroke Res 1:31–34
Fabian C, Sternson L, El-Serafi M, Cain L, Hearne E (1981) Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data. Cancer 48:876–882
Smith CP, Oh JD, Bibbiani F, Collins MA, Avila I, Chase TN (2007) Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates. Neuropharmacology 52:515–526
Zhang Y, Milatovic D, Aschner M, Feustel PJ, Kimelberg HK (2007) Neuroprotection by tamoxifen in focal cerebral ischemia is not mediated by an agonist action at estrogen receptors but is associated with antioxidant activity. Exp Neurol 204:819–827
Atakisi E, Kart A, Atakisi O, Topcu B (2009) Acute tamoxifen treatment increases nitric oxide level but not total antioxidant capacity and adenosine deaminase activity in the plasma of rabbits. Eur Rev Med Pharmacol Sci 13:239–243
Puchner MJ, Giese A, Lohmann F, Cristante L (2004) High-dose tamoxifen treatment increases the incidence of multifocal tumor recurrences in glioblastoma patients. Anticancer Res 24:4195–4203
Sankar T, Caramanos Z, Assina R, Villemure JG, Leblanc R, Langleben A, Arnold DL, Preul MC (2008) Prospective serial proton MR spectroscopic assessment of response to tamoxifen for recurrent malignant glioma. J Neurooncol 90:63–76
Acknowledgment
This study was supported by grants NS-017760, NS-039866 and NS-057539 from the National Institutes of Health (NIH) and 0755717Z, 0840016N from the American Heart Association (AHA). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH and AHA. Dr. Xie was supported by NSFC-30901549 from the China National Natural Science Foundation.
Conflict of interest statement We declare that we have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag/Wien
About this chapter
Cite this chapter
Xie, Q., Guan, J., Wu, G., Xi, G., Keep, R.F., Hua, Y. (2011). Tamoxifen Treatment for Intracerebral Hemorrhage. In: Zhang, J., Colohan, A. (eds) Intracerebral Hemorrhage Research. Acta Neurochirurgica Supplementum, vol 111. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0693-8_45
Download citation
DOI: https://doi.org/10.1007/978-3-7091-0693-8_45
Published:
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-0692-1
Online ISBN: 978-3-7091-0693-8
eBook Packages: MedicineMedicine (R0)